Lupus Foundation of America2d
IGM Biosciences Halts Development of Two Investigational Treatments for People with Autoimmune and Inflammatory Diseases
IGM Biosciences announced the discontinuation of imvotamab and IGM-2644 for autoimmune and inflammatory diseases, including ...
Lupus Foundation of America3d
New Study Highlights Evidence Gaps and Under-Representation in Lupus Nephritis Clinical Trials
In a new study published in Lupus Science & Medicine, researchers reviewed randomized clinical trials (RCTs) to assess ...
Lupus Foundation of America4d
People Living with Systemic Lupus Erythematosus Demonstrate Clinically Meaningful Improvement with Cenerimod
In the Phase 2b CARE study, the investigational drug, cenerimod, demonstrated safe and effective results for treatment of ...
Lupus Foundation of America13d
New Study Identifies Two Potential Non-Invasive Diagnostic Biomarkers for Systemic Lupus Erythematosus and Lupus Nephritis
A new study explored the potential of IncRNA CASC2 and miR-155 levels as non-invasive diagnostic biomarkers for systemic lupus erythematosus (SLE) and lupus nephritis (LN). Previous studies have found ...
Lupus Foundation of America20d
Deucravacitinib Outperforms Other Biologic Therapies for Treatment of Cutaneous Lupus Erythematosus
In a new study, the drug, deucravacitinib, proved to be a safe and more effective treatment for cutaneous lupus erythematosus ...